CAR T-Cell Lymphoma Trial Underway
Apr 2, 2018 9:00 AM
The University of Utah and Huntsman Cancer Institute were just selected as one of the few national cancer centers for a large Novartis and KITE Pharma Inc.-sponsored anti-CD19 CAR T-cell immunotherapy clinical trial focused on relapsed or refractory diffuse large B-cell lymphoma, a form of non-Hodgkin lymphoma. Our Cell Therapy and Regenerative Medicine Program (CTRM) Center will be a key component of this clinical trial. The FDA requires special certification for sites offering CAR T-cell therapy, and only specially trained hospitals and clinics are part of the network of treatment centers.This is an exciting new immunotherapy option for lymphoma patients.